$599

Ionis Q2 ’26 Earnings; FDA Revised Draft Guidance for Generic AOMs; Beta Bionics Q2 ’26 Earnings

Three cardiometabolic-related news items have been observed: Ionis hosted its Q2 ’26 earnings call (press release; slides); FDA published revised draft guidance for 17 peptides (view press release); and Beta Bionics hosted its Q2 ’26 earnings call (view press release; slides). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here